Post by
lonc17 on Feb 03, 2024 7:29pm
Roche
Okay, here's something I missed.
On the "Pipline" page on the Investor Presentation, Oncolytics is showing that Roche is the partner for their pending and promised P3 in pancreatic cancer.
https://oncolyticsbiotech.com/pipeline/
Is this a goof up on ONC's part or is it true?
If it is true, then congratulations, I was wrong, it looks like ONC has the necessary funding and expertise in place to run their P3.
On the other hand, if it is simply an indication that ONC "hopes" to run the P3 using Roche's immunotherapy but has no real commitment from them at this time then it is totally bush league and futher evidence (as if we needed any) that MC is an expert at misleading investors.
Comment by
venture009 on Feb 04, 2024 10:53am
Collaboration and Partnering are two distinctly different and they define the differences in their summation at the end of the Pipeline segment.
Comment by
venture009 on Feb 04, 2024 11:02am
Collaboration and Partnering are two distinctly different and they define the differences in their summation at the end of the Pipeline segment.@
Comment by
Noteable on Feb 04, 2024 10:30pm
This post has been removed in accordance with Community Policy